KLRSHIGH SIGNALMANAGEMENT10-K

KLRS completed a transformative merger with AlloVir, Inc., fundamentally changing from AlloVir's business to become a clinical-stage biopharmaceutical company focused on retinal disease treatments.

This represents a complete business transformation rather than organic growth, as the company changed its name from AlloVir to Kalaris Therapeutics and adopted Legacy Kalaris's retinal disease focus as its primary business. The merger fundamentally alters the investment thesis, moving from AlloVir's previous business model to clinical-stage ophthalmology drug development.

Comparing 2026-03-17 vs 2025-03-07View on EDGAR →
FINANCIAL ANALYSIS

The financial results reflect the post-merger combined entity, showing reduced operating losses and meaningfully improved cash burn with operating cash flow deficit narrowing substantially. However, current liabilities increased notably while stockholders' equity declined by roughly 30%, and cash reserves decreased to $98.1M from $118.3M. The overall financial picture suggests improved operational efficiency post-merger but ongoing cash consumption typical of clinical-stage biotech operations.

FINANCIAL STATEMENT CHANGES
Current Liabilities
Balance Sheet
+85.4%
$5.2M→$9.7M

Current liabilities surged 85.4% — significant near-term obligations; verify ability to meet short-term debt.

Interest Expense
P&L
-46.6%
$2.7M→$1.4M

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Operating Cash Flow
Cash Flow
+43.3%
-$67.7M→-$38.4M

Operating cash flow surged 43.3% — exceptional cash generation, highest quality earnings signal.

Stockholders Equity
Balance Sheet
-30.4%
$113.3M→$78.8M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Operating Income
P&L
+29.5%
-$65.4M→-$46.2M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Net Income
P&L
+26.1%
-$58.8M→-$43.4M

Net income grew 26.1% — bottom-line growth signals improving overall business health.

Cash & Equivalents
Balance Sheet
-17.1%
$118.3M→$98.1M

Cash decreased 17.1% — monitor burn rate and upcoming capital needs.

LANGUAGE CHANGES
NEW — 2026-03-17
PRIOR — 2025-03-07
ADDED
As of March 10, 2026 , the Registrant had 22,928,303 shares of common stock, $0.0001 par value per share, outstanding.
Form 10-K Summary 126 Signatures 127 On March 18, 2025, AlloVir, Inc., a Delaware corporation and our predecessor company, consummated the previously announced merger (the Merger ) pursuant to the terms of the Agreement and Plan of Merger, dated as of November 7, 2024 (the Merger Agreement ), by and among AlloVir, Aurora Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of AlloVir ( Merger Sub ) and Kalaris Tx, Inc.
(formerly Kalaris Therapeutics, Inc.), a Delaware corporation ( Legacy Kalaris ).
In connection with the completion of the Merger, we changed our name from AlloVir, Inc.
to Kalaris Therapeutics, Inc., and our business became primarily the business conducted by Legacy Kalaris.
+7 more — sign up free →
REMOVED
Exhibits, Financial Statement Schedules 125 Item 16 Form 10-K Summary 127 i Special Note On January 15, 2025, we effected a 1-for-23 reverse stock split of our common stock either issued and outstanding or held as treasury stock.
As a result of the reverse stock split, every 23 shares of issued and outstanding common stock were automatically combined into one issued and outstanding share of common stock, without any change in the par value per share.
Stockholders who would otherwise have been entitled to receive fractional shares as a result of the reverse stock split were entitled to a cash payment in lieu thereof at a price equal to the fraction to which the stockholder would otherwise be entitled multiplied by the closing sales price per share of our common stock (as adjusted for the reverse stock split) on The Nasdaq Capital Market on January 15, 2025, the last trading day immediately preceding the effective time of the reverse stock split.
Unless otherwise indicated, all historical share and per share amounts in this Annual Report on Form 10-K have been adjusted to reflect the reverse stock split.
1 Summary of Material Risks Associated with Our Business Our business is subject to numerous risks and uncertainties that you should be aware of before making an investment decision, including those highlighted in the section entitled Risk Factors.
+7 more — sign up free →
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →